Source: Annual Congress 2006 - Recent advances in the treatment of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. A. Wise, M. R. Littner, P. Zhang, S. Mallikaarjun, K. Mitsui, C. Orlandi, N. A. Molfino (Baltimore, Sepulveda, Rockville, United States Of America). Clinical evaluation of a new inhibitor of neutrophilic inflammation, tetomilast (OPC-6535), in chronic obstructive pulmonary disease (COPD). Eur Respir J 2006; 28: Suppl. 50, 3052

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and tolerability of tetomilast, a new inhibitor of neutrophilic inflammation, in chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 526s Year: 2006 Cilomilast is efficacious in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 68s Year: 2003 The systemic inflammation and factors of coagulation in patients with chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – COPD markers Year: 2014 Evidence of mast-cell activation in a subset of patients with eosinophilic chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: 325-331 Year: 2002 Platelets activation during chronic obstructive pulmonary disease (COPD) exacerbation Source: Eur Respir J 2002; 20: Suppl. 38, 89s Year: 2002 Clinical value of C-reactive protein in severe acute exacerbations of COPD Source: Annual Congress 2005 - COPD - acute exacerbations Year: 2005 Local and systemic inflammation in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –Biomarkers in asthma and COPD Year: 2013 Efficacy of erdosteine (E) in the treatment of exacerbated and stable chronic bronchitis or chronic obstructive pulmonary disease (CB/COPD): a meta-analysis of individual patient data Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Systemic and pulmonary inflammation in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Pathophysiology of COPD Year: 2008 Association between adipokines, inflammatory markers and systemic manifestations in chronic obstructive pulmonary disease (COPD) patients Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities Year: 2016 Beyond corticosteroids: future prospects in the management of inflammation in COPD Source: Eur Respir Rev 2011; 20: 175-182 Year: 2011 Biomarkers in the management of COPD Source: Eur Respir Rev 2009; 18: 96-104 Year: 2009 Small airway inflammation in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 501s Year: 2001 The safety of sputum induction in patients with exacerbation of severe and very severe COPD (chronic obstructive pulmonary disease) Source: Annual Congress 2008 - Organisation of care and management of COPD Year: 2008 Therapeutic approaches in the chronic obstructive (COPD) pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 472s Year: 2002 Enalapril in the management of patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 241s Year: 2003 Systemic inflammation and cardiovascular disease in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench Year: 2013 Functional and inflammatory bowel diseases in patients with chronic obstructive pulmonary disease (COPD). Source: International Congress 2019 – Advances in clinical management of COPD Year: 2019 Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 903-908 Year: 2001 Acute effects of sildenafil in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008